-transparent.png){kind=logo}
An in vitro study of how platelet aggregation would be inhibited by the combination of aspirin or ticlopidine irreversibly inhibitory to platelet aggregation and trapidil or dipyridamole reversibly inhibitory, was carried out. The measured 50% inhibition concentrations indicated that aspirin was most inhibitory to collagen-induced platelet aggregation, followed by trapidil, ticlopidine and dipyridamole in decreasing sequence of inhibition. The combination of either aspirin or ticlopidine with trapidil inhibited platelet aggregation more intensely than the combination of either agent with dipyridamole. Thus, in clinical use of aspirin or ticlopidine, it may be expected that the lower dosage of aspirin or ticlopidine with lower frequencies of side effects inhibits platelet aggregation effectively with the combination of trapidil rather than dipyridamole.
Y Nagakawa, and
Y Akedo, and
H Orimo, and
H Yano
January 1987,
Nephron,
Y Nagakawa, and
Y Akedo, and
H Orimo, and
H Yano
January 1986,
Nephron,
Y Nagakawa, and
Y Akedo, and
H Orimo, and
H Yano
April 1985,
Lancet (London, England),
Y Nagakawa, and
Y Akedo, and
H Orimo, and
H Yano
December 1998,
Hematology/oncology clinics of North America,
Y Nagakawa, and
Y Akedo, and
H Orimo, and
H Yano
January 1988,
ASAIO transactions,
Y Nagakawa, and
Y Akedo, and
H Orimo, and
H Yano
May 1989,
Rinsho shinkeigaku = Clinical neurology,
Y Nagakawa, and
Y Akedo, and
H Orimo, and
H Yano
March 1998,
Circulation,
Y Nagakawa, and
Y Akedo, and
H Orimo, and
H Yano
October 1999,
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
Y Nagakawa, and
Y Akedo, and
H Orimo, and
H Yano
November 1999,
PharmacoEconomics,
Y Nagakawa, and
Y Akedo, and
H Orimo, and
H Yano
January 1983,
Therapie,
